Novartis (NVS) halted eight CAR-T autoimmune clinical trials in late August after three patients died from severe immune responses, casting doubt on the Swiss drugmaker’s push into a fast-growing therapeutic category.
The pause raises material questions about the commercial timeline for Novartis’s autoimmune pipeline and adds regulatory risk at a moment when the broader sector is racing to translate cancer-proven CAR-T technology into new disease categories.1
Key Takeaways
- Three patient deaths triggered a halt across eight Novartis CAR-T trials.
- Bristol-Myers Squibb also paused comparable autoimmune CAR-T studies.
- Fatal immune response is a known, class-wide CAR-T safety risk.
Market Reaction & Context
Novartis’s setback lands alongside a parallel pause by Bristol-Myers Squibb (BMY) in its own autoimmune CAR-T programme – a rare simultaneous halt that signals the immune-response risk may be structural rather than company-specific.2 The coincidence of two major pharma players stopping comparable studies on similar timelines is likely to weigh on sentiment across the cell-therapy sub-sector, which has attracted significant capital on the promise of CAR-T’s cancer success translating to autoimmune disorders.
Investors tracking biotech consolidation themes should note that safety-driven trial pauses have historically suppressed acquisition multiples for affected platforms, even when studies ultimately resume. The broader CAR-T autoimmune field – which counts several mid-cap biotechs among active developers – could face re-pricing if regulators impose tighter hold criteria.
What Went Wrong
CAR-T therapy works by extracting a patient’s T-cells, engineering them to recognise a specific target, and reinfusing them to eliminate diseased tissue – a mechanism that has proven effective in blood cancers but carries an inherent risk of triggering runaway immune activation.2 Novartis said the three deaths resulted from a severe immune response, a reaction its spokesman described to the Wall Street Journal as “a known safety risk in CAR-T therapies.”
The eight paused trials were targeting autoimmune and neurological disorders – a strategic frontier for Novartis that sits at the intersection of high unmet medical need and premium pricing potential. It was not immediately clear when the three deaths occurred, the Journal said.1
The trial halts are a reminder that extending CAR-T from oncology to autoimmune indications is not straightforward. Safety profiles established in cancer patients – who often have few treatment alternatives – may not translate to patients with chronic but non-fatal conditions, where regulators and ethics boards apply stricter risk tolerances. This dynamic has also surfaced in gene therapy, where unexpected adverse events have derailed programmes and depressed developer valuations.
Competitive Positioning & Autoimmune Push
The setback sharpens scrutiny on a sector-wide bet: that CAR-T’s proven mechanism in haematological cancers can be adapted to reset the immune system in conditions such as lupus, myositis, and multiple sclerosis. Kyverna Therapeutics, Cartesian Therapeutics, and several academic spin-outs are among the smaller players developing competing autoimmune CAR-T approaches, and a class-level safety signal from two large-cap sponsors could freeze investor appetite for earlier-stage programmes.
The autoimmune space has simultaneously attracted conventional biologics competition. Johnson & Johnson’s recent approval of Imaavy for rare blood disorders illustrates the intensity of the race to capture autoimmune market share using distinct mechanisms – a rivalry that may benefit from CAR-T’s current stumble.
Management Response & Regulatory Outlook
“Novartis is conducting a comprehensive review of the observed safety events,” a company spokesman said, according to the Wall Street Journal, adding that the fatal immune response is “a known safety risk in CAR-T therapies.”1
The company said it is working with independent safety monitoring boards overseeing each of the eight paused studies and is sharing findings with regulators.2 Neither Novartis nor Bristol-Myers Squibb responded to Reuters requests for comment at the time of reporting.
Regulatory agencies typically require a comprehensive safety data review before allowing paused studies to resume, a process that can take weeks to months depending on the complexity of the adverse-event analysis and the number of sites involved. Each additional delay compresses the development timelines that underpin Novartis’s long-range autoimmune revenue projections.
Conclusion
The simultaneous halts by Novartis and Bristol-Myers Squibb represent the most significant public setback yet for the autoimmune CAR-T thesis, and the outcome of both companies’ safety reviews will likely set the template for how regulators approach the broader category going forward. For investors tracking biotech consolidation velocity, the episode complicates near-term deal math for any acquirer weighing CAR-T autoimmune assets while class-level risk remains unresolved.
Not investment advice. For informational purposes only.
References
1(2026-09-01). “Novartis Pauses Autoimmune Cell Therapy Studies After Deaths”. The Wall Street Journal. Retrieved 2026-09-01.
2Shivani Tanna (2026-09-01). “Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports”. Reuters / KFGO. Retrieved 2026-09-01.